David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Oct 26, 2026, 16:40Elena Torre: Rethinking Iron Management in Polycythemia Vera
-
Oct 26, 2026, 16:31Tara King: Building Connections in Transfusion Medicine at AABB
-
Oct 26, 2026, 16:16Wendy Jean Schell: How Genetics and Supplements May Influence Bleeding Risk
-
Oct 26, 2026, 15:37Sally Mandour: Lupus Anticoagulant-The Tree Key Diagnostic Criteria
-
Oct 26, 2026, 15:37Aryabhatta Sadhu: Intrauterine Red-Cell and Platelet Transfusion in Fetal Medicine
-
Oct 26, 2026, 15:25Christine Tunkl: Telestroke – Expanding Access to Evidence-Based Stroke Care
-
Oct 26, 2026, 15:13Heghine Khachatryan: Approaching Thrombocytopenia Through Mechanism and Clinical Context
-
Oct 26, 2026, 15:03Quentin Eichbaum։ AABB 2026 Annual Meeting Personal Highlights
-
Oct 26, 2026, 14:57A Father’s Marathon Journey Inspired by His Son – National Bleeding Disorders Foundation